Systemic therapy, radiotherapy, and cardiotoxicity

Cardiac Tumor Pathology

Volumn , Issue , 2013, Pages 165-182

  Lestuzzi, Chiara ^a   Miolo, Gianmaria ^a   De Paoli, Antonino ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879076817     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-143-1_12     Document Type: Chapter

References (100)

1. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393-408.
2. Tilly H, Dreyling M, ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v172-4.
3. Llombart-Cussac A, Pivot X, Contesso G, Rhor- Alvarado A, Delord JP, Spielmann M, Tursz T, Le Cesne A. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer. 1998;78:1624-8.
4. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C. Tumeurs cardiaques malignes. Bull Cancer. 2004;91:S136-46.
5. Simpson L, Kumar SK, Okuno SH, Schaff HV, Porrata LF, Buckner JC, Moynihan TJ. Malignant primary cardiac tumors. Review of a single institution experience. Cancer. 2008;112:2440-6.
6. Kim CH, Dancer JY, Coffey D, Zhai QJ, Reardon M, Ayala AG, Ro JY. Clinicopathologic study of 24 patients with primary cardiac sarcomas: a 10-year single institution experience. Hum Pathol. 2008;39:933-8.
7. Truong PT, Jones SO, Martens B, Alexander C, Paquette M, Joe H, Hart J, Allan SJ. Treatment and outcomes in adult patients with primary cardiac sarcoma: the British Columbia Cancer Agency experience. Ann Surg Oncol. 2009;16:3358-65.
8. Mayer F, Aebert H, Rudert M, Königsrainer A, Horger M, Kanz L, Bamberg M, Ziemer G, Hartmann JT. Primary malignant sarcomas of the heart and great vessels in adult patients. A single-center experience. Oncologist. 2007;12:1134-42.
9. Hamidi M, Moody JS, Weigel TL, Kozak KR. Primary cardiac sarcoma. Ann Thorac Surg. 2010;90:176-81.
10. Zhang PJ, Brooks JS, Goldblum JR, Yoder B, Seethala R, Pawel B, Gorman JH, Gorman RC, Huang JH, Acker M, Narula N. Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol. 2008;39:1385-95.
11. Vaporciyan A, Reardon MJ. Right heart sarcomas. Methodist Debakey Cardiovasc J. 2010;6:44-8.
12. Reardon MJ. Malignant tumor overview. Methodist Debakey Cardiovasc J. 2010;6:35-7.
13. NCCN Practice Guidelines in Oncology (NCCN GuidelinesTM). Soft tissue sarcomas. Version 1. 2011. http://www.NCCN.org .
14. Casali PG, Blay JY, ESMO/CONTICANET/ EUROBONET Consensus Panel of Experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v198-203 (Erratum in: Ann Oncol. 2010;21:1736).
15. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized soft tissue sarcoma. Cancer. 2008;113:573-81.
16. Blackmon SH, Reardon MJ. Pulmonary artery sarcoma. Methodist Debakey Cardiovasc J. 2010;6:38-43.
17. Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DA. Primary cardiac sarcomas. Ann Thorac Surg. 1991;51:906-10.
18. Burke AP, Cowan D, Virmani R. Primary sarcomas of the heart. Cancer. 1992;69:387-95.
19. Donsbeck A-V, Ranchere D, Coindre J-M, Le Gall F, Cordier J-F, Loire R. Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. Histopathology. 1999;34:295-304.
20. Centofanti P, Di Rosa E, Deorsola L, Dato GM, Patanè F, La Torre M, Barbato L, Verzini A, Fortunato G, di Summa M. Primary cardiac tumors: early and late results of surgical treatment in 91 patients. Ann Thorac Surg. 1999;68:1236-41.
21. Bakaeen FG, Reardon MJ, Coselli JS, Miller CC, Howell JF, Lawrie GM, Espada R, Ramchandani MK, Noon GP, Weilbaecher DG, DeBakey ME. Surgical outcome in 85 patients with primary cardiac tumors. Am J Surg. 2003;186:641-7.
22. Huo L, Moran CA, Fuller GN, Gladish G, Suster S. Pulmonary artery sarcoma. Am J Clin Pathol. 2006;125:419-24.
23. Neragi-Miandoab S, Kim J, Vlahakes GJ. Malignant tumors of the heart: a review of tumor type, diagnosis and therapy. Clin Oncol. 2007;19:748-56.
24. Thomas-de-Montpréville V, Nottin R, Dulmet E, Serraf A. Heart tumors in children and adult s: clinicopathological study of 59 patients from a surgical center. Cardiovasc Pathol. 2007;16:22-8.
25. Kim HK, Choi YS, Kim K, Shim YM, Sung K, Lee YT, Park PW, Kim J. Surgical treatment for pulmonary artery sarcoma. Eur J Cardio-Thoracic Surg. 2008;33:712-6.
26. Blackmon SH, Rice DC, Correa AM, Mehran R, Putnam JB, Smythe WR, Walkes JC, Walsh GL, Moran C, Singh H, Vaporciyan AA, Reardon M. Management of primary pulmonary artery sarcomas. Ann Thorac Surg. 2009;87:977-84.
27. Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher SS, Benjamin R, Blackmon S, Reardon MJ. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg. 2009;137:1454-60.
28. Orlandi A, Ferlosio A, Roselli M, Chiariello L, Spagnoli LG. Cardiac sarcomas. An update. J Thorac Oncol. 2010;5:1483-9.
29. Blackmon SH, Patel AR, Bruckner BA, Beyer EA, Rice DC, Vaporciyan AA, Wojciechowski Z, Correa AM, Reardon MJ. Cardiac autotransplantation for malignant or complex primary left-heart tumors. Tex Heart Inst J. 2008;35:296-300.
30. Kopp HG, Patel S, Brücher B, Hartmann JT. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol. 2008;9:207-17.
31. Chao J, Chow WA, Somlo G. Novel targeted therapies in the treatment of soft-tissue sarcomas. Expert Rev Anticancer Ther. 2010;10:1303-11.
32. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14:285-94.
33. Ravi V, Benjamin RS. Systemic therapy for cardiac sarcomas. Methodist Debakey Cardiovasc J. 2010;6:57-60.
34. Ganjoo K, Jacobs C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer. 2010;116:1177-83.
35. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie- Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the ef fi cacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;15:7669-74.
36. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte macrophage colony-stimulating factor in advanced soft-tissue sarcomas: a trial of the EORTC-STBSG. J Clin Oncol. 2000;18:2676-84.
37. Schütte J, Mouridsen HT, Stewart W, Santoro A, van Oosterom AT, Somers R, Blackledge G, Verweij J, Dombernowsky P, Thomas D. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1990;26:558-61.
38. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182.
39. Casali P, Pastorino U, Azzarelli A, Bertulli R, Zucchinelli P, Devizzi L, Santoro A. Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 1993;31 Suppl 2:S228-32.
40. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: metaanalysis of individual data. Lancet. 1997;350:1647-54.
41. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-47.
42. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003;CD003293
43. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B. Dose response evaluation of Adriamycin in human neoplasia. Cancer. 1977;39:1940-8.
44. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft-tissue sarcomas: results of phase II and pilot studies-dose response and schedule dependence. J Clin Oncol. 1997;15:2378-84.
45. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of 2 consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317-21.
46. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 1993;53:3765-70.
47. Garcia AA, Kempf RA, Rogers M, Muggia FM. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol. 1998;9:1131-3.
48. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil ™ ) in sarcoma. Cancer Invest. 2003;21:167-76.
49. Skubitz M, Haddad PA. Paclitaxel and pegylatedliposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;15:361-6.
50. Eiling S, Lischner S, Busch J-O, Rothaupt D, Christophers E, Hauschild A. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Brit J Derm. 2002;147:150-3.
51. Verdier E, Carvalo P, Young P, Musette P, Courville P, Joly P. Lymphangiosarcoma treated with liposomal doxorubicin. Ann Dermatol Venerol. 2007; 134:760-3.
52. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule- affecting drug paclitaxel has anti-angiogenic activity. Clin Cancer Res. 1996;2:1843-9.
53. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft-tissue sarcomas and window evaluation of dose-rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483-9.
54. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-31.
55. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, KerbratP, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the AngioTax study. J Clin Oncol. 2008;26:5269-74.
56. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PCW, Marreaud S, Van Glabbeke M, Blay JY. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur Jof Cancer. 2008;44:2433-6.
57. Bocci G, Nicolaou KC, Kerbel RS. Protracted lowdose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938-43.
58. Browder T, Butter fi eld CE, Kräling BM, Shi B, Marshall B, O'Reilly MS. Anti-angiogenic scheduling of chemotherapy improves ef fi cacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-86.
59. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR. Randomized phase II study of docetaxel versus doxorubicin in fi rst-line and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2081-6.
60. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154-60.
61. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-40.
62. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148-53.
63. Penel N, Marreaud S, Robin YM, Hohenberger P. Angiosarcoma: state of the art and prospectives. Crit Rev Oncol/Hematol 2011;80:257-63.
64. Ordonez JL, Martins AS, Osuna D, Madoz-Gùrpide J, de Alava E. Targeting sarcomas: therapeutic targets and their rational. Sem Diagn Pathol. 2008;25: 304-16.
65. Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, Marks L. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phis. 2010;76(3 Suppl):S77-85.
66. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys. 2002;29:2391-403.
67. Boerma M, Wang J, Wondergem J, Joseph J, Qui X, Kennedy RH, Hauer-Jensen M. In fl uence of mast cells on structural and functional manifestations of radiation-induced heart disease. Cancer Res. 2005;65: 3100-7.
68. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys. 2007;67:10-8.
69. Goitein M. Organ and tumor motion: an overview. Semin Radiat Oncol. 2004;14:2-9.
70. De Paoli A, Lestuzzi C, Santini F, Boz G, Innocente R, Buonadonna A, Canzonieri V, Frustaci S. Primary cardiac sarcomas: experience with an evolving multidisciplinary approach with focus on the radiation therapy component. In: Proceedings of the 16th connective tumors oncology society annual meeting, 2010; #60. p. 118.
71. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
72. Simunek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154-71.
73. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37: 300-11.
74. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981;102:709-18.
75. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-79.
76. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-5.
77. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol. 2008;21: 978-89.
78. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;16:CD003917.
79. Grenader T, Goldberg A, Hadas-Halperin I, Gabizon A. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs. 2009;20:15-20.
80. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950-61.
81. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
82. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, Foley B, Bourge RC. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:2196-201.
83. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-81.
84. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213-20.
85. Wells QS, Lenihan DJ. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cradiovasc Dis. 2010;53:140-8.
86. Quezado ZMN, Wilson WH, Cunnion RE, Parker MP, Reda D, Bryant G, Ognibene FP. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Int Med. 1993;118:31-6.
87. Saintigny P, Chouhania K, Charniot J-C, Breau JL. Cardiovascular toxicity of some cancer agents (others than anthracyclines, fl uoropyrimidines and trastuzumab). Bull Cancer. 2004;91:S174-84.
88. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12:1351-60.
89. Sayed-Ahmed MM, Darweesh AQ, Fatani AJ. Carnitine de fi ciency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi syndrome rat model. Oxid Med Cell Longev. 2010;3:266-74.
90. Raisch DW, Campbell W, Garg P, Qureshi ZP, Bookstaver PB, Norris LAB, Bennet CL. Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf. 2011;10:521-8.
91. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927-34.
92. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010;15: 130-41.
93. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs. 2011;25:159-69.
94. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10:111-26.
95. Hasinoff BB, Patel D. Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol. 2010;10:1-8.
96. Hasinoff BB, Patel D. The lack of target speci fi city of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol. 2010;249:132-9.
97. Berry GJ, Jorden M. Pathology of radiation and anthracycline cardiotoxicity. Pediatr Blood Cancer. 2005;44:630-7.
98. Fajardo LF, Stewart JR. Capillary injury preceding radiation-induced myocardial fi brosis. Radiology. 1971;101:429-33.
99. Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63:214-23.
100. Veinot JP, Edwards WD. Pathology of radiationinduced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766-75.